EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor

Terri L Morton iD, Oscar L Laskin, Diksha Kaushik, Lucy Lee, Jiyuan Ma, Allan Kristensen, Kylie O'Keefe, Lee Golden, Matthew Klein, Ronald Kong iD

Pharmacology Research & Perspectives · 2023

DOI: 10.1002/prp2.1076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Terri L Morton und 9 weiteren Autor:innen. Beteiligte Einrichtung: PTC Therapeutics, South Plainfield, New Jersey, USA. Hauptthemen laut MEDLINE: Dihydroorotate Dehydrogenase, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PTC Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A therapeutic agent that targets both viral replication and the hyper‐reactive immune response would offer a highly desirable treatment for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; COVID‐19) management. Emvododstat (PTC299) was found to be a potent inhibitor of immunomodulatory and inflammation‐related processes by the inhibition of dihydroorotate dehydrogenase (DHODH) to reduce SARS‐CoV‐2 replication. DHODH is the rate‐limiting enzyme of the de novo pyrimidine nucleotide biosynthesis pathway. This drug interaction study was performed to determine whether emvododstat was an inhibitor of breast cancer resistance protein (BCRP) transporters in humans. Potential drug–drug interactions (DDIs) between emvododstat and a BCRP transporter substrate (rosuvastatin) were investigated by measuring plasma rosuvastatin concentrations before and after emvododstat administration. There was no apparent difference in rosuvastatin plasma exposure. The geometric means of maximum plasma rosuvastatin concentrations (C max ) were 4369 (rosuvastatin) and 5141 pg/mL (rosuvastatin + emvododstat) at 4 h postdose. Geometric mean rosuvastatin area under the concentration–time curve (AUC) from time 0 to the last measurable plasma concentration was 45 616 and 48 975 h·pg/mL when administered alone and after 7 days of b.i.d. emvododstat dosing, respectively. Geometric least squares mean ratios for C max and AUC were approximately equal to 1. Overall, administration of multiple doses of 100 mg emvododstat b.i.d. for 7 days in combination with a single dose of rosuvastatin was safe and well tolerated. Emvododstat can be safely administered with other BCRP substrate drugs. Hence, pharmacokinetic DDI mediated via BCRP inhibition is not expected when emvododstat and BCRP substrates are coadministered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydroorotate DehydrogenaseCOVID-19HumansRosuvastatin CalciumATP Binding Cassette Transporter, Subfamily G, Member 2SARS-CoV-2PyrimidinesNeoplasm ProteinsMembrane Transport ProteinsDrug InteractionsCarbamatesCarbazoles

Stichwörter der Autor:innen

BCRPCOVID-19DHODHPTC299SARS-CoV-2coronaviruspharmacokinetics

Substanzen

Rosuvastatin CalciumATP Binding Cassette Transporter, Subfamily G, Member 2Dihydroorotate DehydrogenasePyrimidinesNeoplasm ProteinsMembrane Transport ProteinsemvododstatCarbamatesCarbazoles

Autor:innen und Institutionen

  • PTC Therapeutics, South Plainfield, New Jersey, USA.

ORCID-Profile: Terri L Morton, Ronald Kong

Förderung

  • PTC Therapeutics

Zitieren

APA

Morton, T. L., Laskin, O. L., Kaushik, D., Lee, L., Ma, J., Kristensen, A., O'Keefe, K., Golden, L., Klein, M., & Kong, R. (2023). A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1076

Vancouver

Morton TL, Laskin OL, Kaushik D, Lee L, Ma J, Kristensen A, et al. A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1076

BibTeX
@article{Morton2023,
  author = {Morton, Terri L and Laskin, Oscar L and Kaushik, Diksha and Lee, Lucy and Ma, Jiyuan and Kristensen, Allan and O'Keefe, Kylie and Golden, Lee and Klein, Matthew and Kong, Ronald},
  title = {A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor},
  journal = {Pharmacology Research & Perspectives},
  year = {2023},
  doi = {10.1002/prp2.1076}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche